MCKESSON CORPORATION - EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 OCTOBER
Key Details
Description
EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 OCTOBER
Context & Analysis
On Oct 1, 2025, Department of Veterans Affairs obligated $1,184,200,532.33 to MCKESSON CORPORATION for express report: pharmaceutical prime vendor (ppv)fy2026 october. The award is classified under NAICS 325412 — PHARMACEUTICAL PREPARATION MANUFACTURING and issued as a firm fixed price contract. Competition extent: full and open competition. Performance is located in IRVING, TX. This award is one of several similar procurements from Department of Veterans Affairs under NAICS 325412 — related awards are listed below.
Market context
- Recompete outlook
- Ended Oct 31, 2025 (12 months ago). Recompete signal as of Oct 25, 2026: 50/100, combining time to the end date, the incumbent's history with this agency, whether the award was competed, and its size.
- Competition
- Competed. 90% of 994 awards in this market (Department of Veterans Affairs awards in NAICS 325412 over the last 3 years) were competed; median 3 offers.
- Award size
- At $1.2B, this award is larger than 19 in 20 of the 878 priced Department of Veterans Affairs awards in NAICS 325412 over the last 3 years (median $165K).
- Incumbent at this agency
- MCKESSON CORPORATION has 5 other awards from Department of Veterans Affairs, totalling $3.6B, 2025–2026.
- Largest vendors in this market
By obligations, Department of Veterans Affairs awards in NAICS 325412 over the last 3 years.
- EXELAN PHARMACEUTICALS INC — 58 awards, $111.4M
- PROGENICS PHARMACEUTICALS INC — 49 awards, $60.4M
- CARDINAL HEALTH 414, LLC — 76 awards, $39.1M
- NOVARTIS PHARMACEUTICALS CORPORATION — 26 awards, $31.6M
- SOFIE CO. — 23 awards, $19.6M
Computed from USAspending award data on Oct 25, 2026.
Contractor Information
Similar Awards
EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 NOVEMBER
MCKESSON CORPORATION
$1.4B
EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 DECEMBER
MCKESSON CORPORATION
$1.1B
EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 JANUARY
MCKESSON CORPORATION
$1.1B
LENALIDOMIDE FOR THE SALISBURY VAMC, CHARLOTTE HCC, AND KERNERSVILLE HCC.
EXELAN PHARMACEUTICALS INC
$5.1M
LENALIDOMIDE CAPSULES
EXELAN PHARMACEUTICALS INC
$4.8M
Stay Updated
Get notified about new opportunities matching your interests.